A long-running securities class action alleging Pfizer Inc. (NYSE:PFE) hid health risks associated with painkiller drugs faces an uncertain future after a New York federal judge threw out a crucial damages report by the plaintiffs’ expert witness. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 1.27%. On last trading day company shares ended up $29.49. Analysts mean target price for the company is $33.97. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -3.41%.
Effective May 15, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) granted an exemption to BlackRock, Inc., together with its subsidiaries, affiliates and associates (collectively, “BlackRock”) under the Company’s Section 382 Rights Agreement, dated as of October 31, 2013, between the Company and Computershare Trust Company, N.A., as rights agent (the “Rights Agreement”) following the determination by a designated committee of the Board of Directors (the “Board”) of the Company that BlackRock and the various investment funds and accounts for which BlackRock acts, or may in the future act, as manager and/or investment advisor, are collectively an “Exempt Person” pursuant to Section 29 of the Rights Agreement. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -0.63% in last trading session and ended the day on $6.30. ARIA gross Margin is 78.90% and its return on assets is -65.80%.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -27.00%.
Bristol-Myers Squibb Co (NYSE:BMY) has announced that it will be presenting new clinical data on a number of rheumatology innovations at the forthcoming European League against Rheumatism (EULAR) annual meeting. During the event in Paris from June 11th to 14th 2014, the company will present 20 abstracts on its pioneering T-cell co-stimulation modulator Orencia and investigational selective IL-6 cytokine inhibitor clazakizumab, both of which are therapies for rheumatoid arthritis (RA). Bristol-Myers Squibb Co (NYSE:BMY) shares moved down -0.02% in last trading session and was closed at $48.79, while trading in range of $48.57 – $49.09. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is -7.56%.
MannKind (NASDAQ:MNKD) VP Juergen Martens sold 76,899 shares of the company’s stock on the open market in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $7.50, for a total transaction of $576,742.50. Following the sale, the vice president now directly owns 139,024 shares of the company’s stock, valued at approximately $1,042,680. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $7.77. Company weekly volatility is calculated as 5.49% and price to cash ratio as 84.35.MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 10.68%.
Spherix Incorporated (NASDAQ:SPEX) an intellectual property development company committed to the fostering and monetization of intellectual property, commenced litigation against Juniper Networks, Inc. (NYSE: JNPR), in the United States District Court for the District of Delaware, alleging that the Sunnyvale, California based company infringes five patents owned by Spherix. Spherix Inc. (NASDAQ:SPEX) weekly performance is -1.95%. On last trading day company shares ended up $1.51. Analysts mean target price for the company is $1.00. Spherix Inc. (NASDAQ:SPEX) distance from 50-day simple moving average (SMA50) is -38.66%.
Leave a Reply